# Marius Ardeleanu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marius-ardeleanu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,536 |
| Field | Dermatology and Skin Diseases |
| h-index | 34 |
| i10-index | 48 |
| Last Known Institution | Regeneron (United States) |
| OpenAlex ID | https://openalex.org/A5032594802 |
| ORCID iD | 0000-0002-7712-6862 |
| Works | 163 |

## Researcher papers

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis](https://scholariq.org/papers/peak-pruritus-numerical-rating-scale-psychometric-validation-and-responder/)
- [Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults](https://scholariq.org/papers/patient-burden-of-moderate-to-severe-atopic-dermatitis-ad-insights-from-a-phase/)
- [A basophil-neuronal axis promotes itch](https://scholariq.org/papers/a-basophil-neuronal-axis-promotes-itch/)
- [Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study](https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/)
- [IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis](https://scholariq.org/papers/il-4r-blockade-by-dupilumab-decreases-staphylococcus-aureus-colonization-and/)
- [One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis](https://scholariq.org/papers/one-year-insights-into-the-globostad-multinational-prospective-observational/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)

## Researcher university

- [Regeneron (United States)](https://scholariq.org/institutions/regeneron-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.